





JULY 22, 2020

MRM Health appoints Dr. Werner Cautreels as Chairman and Dr. Nigel Horscroft as Chief Scientific Officer











MRM Health appoints Dr. Werner Cautreels as Chairman and Dr. Nigel Horscroft as Chief Scientific Officer.

Ghent, Belgium - July 22, 2020 - Microbiome specialist MRM Health is pleased to announce the appointment of its Chairman of the Board and its Chief Scientific Officer.

MRM Health NV, a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome, announced today that Dr. Werner Cautreels, former CEO of Solvay Pharmaceuticals and Selecta Biosciences, has been appointed as Chairman of the Board and Dr. Nigel Horscroft, ex-Curevac and Pfizer, as Chief Scientific Officer. In addition, Dr. Ludo Haazen is joining the R&D organization to support clinical development and medical affairs.

"Werner, Nigel and Ludo bring a wealth of additional experience and validation to MRM Health. They each have broad knowledge and experience in their field and will play a key strategic role to advance the company pipeline and get into the clinic. We are delighted to have them on board." said Sam Possemiers, CEO and co-founder of MRM Health.

Dr. Werner Cautreels brings over 40 years of broad industry experience across both biotech and large pharmaceutical companies. Until his retirement in December 2018 he acted as President and CEO of Selecta Biosciences. Previously, he was global head of R&D of Solvay Pharmaceuticals and became in 2005 CEO of Solvay Pharmaceuticals until it was acquired by Abbott Laboratories in 2010. Prior to joining Solvay he was employed by Sanofi, Sterling Winthrop and Nycomed-Amersham in a variety of R&D senior management positions in Europe and in the United States. Dr. Cautreels has acted as Director in various companies, among which Galapagos, Seres and Innogenetics.

"I am very excited to join the Board and the team of MRM Health, and to contribute with my experience to the advancement of its product candidates into the clinic. MRM Health's unique approach and technology has the potential to make a real difference in the field" said Dr. Werner Cautreels.

Dr. Nigel Horscroft has 20 years of drug discovery experience across a variety of therapeutic areas. He joined MRM Health from CureVac AG, Tubingen, Germany, where, as Area Head and Vice President - Molecular Therapy, he contributed to cutting edge therapies in liver disease, infectious disease, rare disease, oncology and ophthalmology. Prior to this, he served as Head of Research at PiKe Pharma in Switzerland. He has also worked at Pfizer in the UK and Valeant Pharmaceuticals in the US. Dr. Horscroft holds a DPhil in Biochemistry from Oxford University and was a post-doctoral researcher at the University of California.



Dr. Ludo Haazen is a seasoned expert in international medicinal drug development with over 30 years of experience in leading international clinical research, pharmacovigilance activities and medical affairs. He has worked for large pharmaceutical companies such as Roche, Janssen Pharmaceutica and UCB, and more recently for leading biotech companies like TiGenix, Ablynx and Actobio, in various senior positions. He holds a Medical Degree from the Catholic University of Leuven (KU Leuven) and a post-graduate certificate in Statistics and Epidemiology. Ludo is also lecturer in Pharmaceutical Medicine at the Free University of Brussels (ULB) and review editor for the scientific journal Frontiers in Pharmacology.

For further information -

Dr Sam Possemiers – CEO Christiane Verhaegen - CFO

Phone: +32.3.241.11.88

info@mrmhealth.com

\*\* END\*\*

## **About MRM Health**

MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with VIB, an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications.

MRM Health combines a number of proprietary innovative technologies as its discovery engine. This includes direct access to the most advanced simulator of the human gut, the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®), allowing to model the complete intestine and its microbiome in the lab, in both health and disease. In addition to multiple academic and expert advisor partnerships, MRM Health also leverages, through the strategic VIB partnership, the extensive microbiome and bioinformatics capabilities of the VIB-KU Leuven lab of prof. Jeroen Raes and the multidisciplinary knowhow in inflammatory diseases and patient insights of prof. Dirk Elewaut (VIB-UGent).

To overcome critical bottlenecks currently hampering microbiome-based product development, MRM Health has developed a unique and differentiating platform for the discovery and development of novel microbiome-based therapeutics and has set up a diversified pipeline. Its most advanced program is MH002, a drug candidate for Inflammatory Bowel Disease (IBD), which includes Ulcerative Colitis (UC) and Crohn's disease (CD). MH002 is an optimized consortium of bacteria, consisting of 6 rationally selected and well-characterized commensal strains.

MRM Health additionally has ongoing discovery programs in Spondyloarthritis and specific metabolic diseases and is targeting several other medical conditions with unmet medical need. In addition to the drug candidates, its pipeline includes two advanced single strain probiotics with differentiating Mode-of-Action and advanced development status for the medical nutrition / OTC and consumer markets (PD01 and PD12).

MRM Health has a corporate collaboration with DuPont Nutrition Biosciences in the discovery and development of microbiome-based therapeutics in the field of metabolic diseases. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB.